Developer docs
API playgroundTry for free, no card

Search company profiles

Sofinnova Investments

Full company profile

uuid000024g

Namestring
Sofinnova Investments
Legal namestring
Sofinnova Investments, Inc.
Websiteurl
sofinnova.com
Company typeenum
Private
Founded yearint
1972
Descriptiontext

Sofinnova Investments is a US healthcare investment firm headquartered at 3000 Sand Hill Road in Menlo Park, California, founded in 1972 in Paris and operating in the US since 1976. Following the 1997 separation of the original Sofinnova group into independent US (Sofinnova Ventures) and Paris (Sofinnova Partners) entities, Sofinnova Investments has been the US successor firm. The firm invests in late preclinical and clinical therapeutic companies across the US and Europe in oncology, respiratory, dermatology, ophthalmology, neurology, and women's health, with a cumulative track record of 118 companies funded, 55 IPOs, 30 M&As, and 33 FDA drug approvals. Notable exits include Karuna Therapeutics→Bristol Myers Squibb ($14B), CinCor→AstraZeneca ($1.8B), RayzeBio→BMS, Akouos→Lilly, Audentes→Astellas, Spark→Roche, Principia→Sanofi, and Capstan→AbbVie (June 2025).

The firm operates a two-platform model: a private-markets venture capital platform organized around successive fund vintages (Funds IV through XII, with Fund X at $650M in 2016 the largest disclosed), and a public-markets platform (Synergy Fund) launched in 2017 as an all-cap, value-oriented, long/short global therapeutics hedge fund with emphasis on mid- and small-cap companies. Approximately $4.6B in assets under management and committed capital is managed as of 9/30/2025. Revenue is generated via management fees on committed capital plus performance-based carried interest on exits; LPs access information through a dedicated Investor Portal. Sofinnova's investment team is "mostly comprised of doctors and doctorate holders," and partners hold meaningful board seats in portfolio companies, providing operational support across drug development, FDA/EMA navigation, company building, and IPO/M&A execution. The firm operates regional offices in Boston (Seaport) and New York, with a previously opened La Jolla office whose current operational status is unconfirmed; a tier-1 co-investor ecosystem includes Viking Global Investors, ARCH Venture Partners, Fidelity, Forbion, Novo Holdings, B Capital, RA Capital, Mubadala, and Perceptive Advisors.

Short descriptiontext

Sofinnova Investments is a US healthcare investment firm managing approximately $4.6B across a private venture capital platform (Funds IV–XII) and the Synergy Fund public-equity hedge fund, backing late preclinical and clinical therapeutic companies in the US and Europe. The firm has funded 118 companies, producing 55 IPOs, 30 M&As, and 33 FDA approvals, including the $14B Karuna→BMS exit.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital, healthcare investing, biotech investment, therapeutic development, life science funding
Industry1 code
PRIMARYFSANAGAG
Endowment / OCIO-Style Multi-Manager Platforms
Financial & Insurance/Private Equity & Venture Capital/Fund-of-Funds / Multi-Manager Platforms
NAICS code1 code
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital - Healthcare/Biotech Investment
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Private Equity Investment Returns
TypeLicensing Royalties
Description

Primary revenue stream: capital appreciation and exit proceeds from investments in late preclinical and clinical therapeutic companies across the U.S. and Europe. Realized through IPOs (e.g., Karuna, CinCor, RayzeBio, Aerovate, Bolt, Athira, Vera, Inozyme, NuCana, Principia, Entasis, Iterum, Y-mAbs, Ascendis, Apellis) and M&A acquisitions (e.g., Karuna→BMS $14B, CinCor→AstraZeneca $1.8B, RayzeBio→BMS, Akouos→Lilly, Audentes→Astellas, Spark→Roche, Tesaro→GSK, Principia→Sanofi, Promedior→Roche, Capstan→AbbVie, Gyroscope→Novartis). 55 IPOs and 30 M&As to date.

sofinnova.com
2Public Equity Hedge Fund
TypeManaged Services
Description

All-cap, value-oriented, long/short global therapeutics hedge fund launched in 2017 with emphasis on mid and small-cap companies. Generates management fees and performance-based returns through the Synergy Fund and related public equity strategies.

sofinnova.com
3Fund Management Fees & Carry
TypeManaged Services
Description

Sofinnova raises successive venture funds (Funds IV through XII, with Fund X being the largest at $650M in 2016) and charges typical private equity management fees and performance carry against approximately $4.6B in assets under management and committed capital (as of 9/30/2025).

sofinnova.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Pricing details1 tier
1Venture Fund X (2016) — largest disclosed fund
ModelOtherBilling cadenceMulti-year contract
Notes

$650M raised; subsequent Funds XI and XII referenced in portfolio entries but specific sizes not publicly disclosed

sofinnova.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Sofinnova Investments is a healthcare-focused investment firm that deploys human and financial capital into late preclinical and clinical therapeutic companies across the U.S. and Europe. It operates a two-platform architecture: a Private Markets venture capital platform that partners with biotech entrepreneurs through every stage of company formation (initial funding, management team building, corporate alliances, IPO and M&A), and a Public Markets hedge fund (Synergy Fund) that pursues an all-cap, value-oriented, long/short global therapeutics strategy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 14 values shown
  • 118 companies funded; 55 IPOs; 30 M&As; 33 FDA drugs approved
+13 more records
Product overview1 text field

Sofinnova Investments operates a two-platform architecture: a Private Markets venture capital platform and a Public Markets hedge fund (Synergy Fund). The Private Markets platform is the core offering, deploying human and financial capital into late preclinical and clinical therapeutic companies across the U.S. and Europe, with key therapeutic areas including oncology, respiratory, dermatology, ophthalmology, neurology, and women's health. The Public Markets platform, launched in 2017, is an all-cap, value-oriented, long/short global therapeutics hedge fund with an emphasis on mid- and small-cap companies. Limited partners access fund information through the Sofinnova Investor Portal (powered by Altareturn). Sofinnova manages approximately $4.6B in assets under management and committed capital, has funded 118 companies, achieved 55 IPOs, 30 M&As, and 33 FDA drug approvals, with 120 years of operating experience and 100 years of investing experience.

Product and service3 records
1Private Markets Platform
CategoryVenture Capital - Therapeutics
Description

Venture capital platform partnering with biotech entrepreneurs in the U.S. and Europe, guiding them through all stages of company formation including initial funding, management team building, corporate alliances, M&A, and IPO. Invests in late preclinical and clinical therapeutic companies across oncology, respiratory, dermatology, ophthalmology, neurology, and women's health. Successive funds IV through XII raised since 1998.

2Public Markets (Synergy Fund)
CategoryPublic Equity Hedge Fund - Therapeutics
Description

All-cap, value-oriented, long/short global therapeutics hedge fund launched in 2017 with an emphasis on mid- and small-cap companies. The fund is managed by the Public Equity team led by General Partner Eric Delbridge, MD.

3Sofinnova Investor Portal
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-28
Description

Originally developed COL-5671 (a SIK3 inhibitor) and fully transferred it to Coultreon Biopharma in April 2025 with an initial seed investment, then participated in Coultreon's $125M Series A. Strategic asset-transfer and co-investor relationship connected to Sofinnova via Coultreon.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-10-09
Description

Granted Expedition Therapeutics (Sofinnova portfolio) exclusive worldwide rights (excluding parts of China) to develop and commercialize EXPD-101, a DPP1 inhibitor for COPD.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-30
Description

Acquired Capstan Therapeutics (Sofinnova portfolio) in 2025 to strengthen commitment to transforming patient care in immunology, representing a major strategic exit.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-09
Description

Entered partnership with City Therapeutics (Sofinnova portfolio) worth up to $1 billion in May 2025, per Fierce Biotech coverage. City Therapeutics planned to supplement its raise through additional partnerships similar to its existing Biogen deal.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-09
Description

Acquired Aiolos Bio (Sofinnova portfolio) in January 2024. Previously acquired TESARO (Sofinnova portfolio). Strategic acquirer of Sofinnova-backed respiratory and oncology assets.

6Bristol Myers Squibb
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-22
Description

Acquired Karuna Therapeutics for $14B (Sofinnova Managing Partner Jim Healy served as board member) and RayzeBio (acquired by BMS to add premier radiopharmaceutical platform). Marquee Sofinnova M&A exit partner.

sofinnova.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-24
Description

Acquired CinCor Pharma (Sofinnova portfolio, Jim Healy was Chairman) for $1.8B; the CinCor acquisition was completed in February 2023. AstraZeneca also subsequently acquired ZS Pharma (Sofinnova portfolio).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-22
Description

Acquired Gyroscope Therapeutics (Sofinnova portfolio) for up to $1.5B to expand its ophthalmology gene therapy capabilities; Gyroscope acquisition completed February 2022. Novartis also previously acquired Ziarco (Sofinnova portfolio).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-01
Description

Acquired Akouos (Sofinnova portfolio, completed Dec 2022) to expand efforts in genetic hearing loss treatments. Previously partnered with NextCure (Sofinnova portfolio) on immuno-oncology discovery (Nov 2018) and with BioAge (Sofinnova portfolio) on multi-year collaboration for age-related disease targets (Dec 2024).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-31
Description

Completed acquisition of Checkmate Pharmaceuticals (Sofinnova portfolio) in May 2022. Strategic acquirer of Sofinnova-backed immuno-oncology assets.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-28
Description

Acquired Amplyx Pharmaceuticals (Sofinnova portfolio, completed Apr 2021) and NextWave Pharmaceuticals (Sofinnova portfolio) for pediatric ADHD therapeutics. Acquired Metsera (referenced in 2026 outlook context as a $10B obesity biotech acquisition).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-11-05
Description

Acquired VelosBio (Sofinnova portfolio) in November 2020 to add ROR1-directed antibody drug conjugates for oncology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-09-28
Description

Completed acquisition of Principia Biopharma (Sofinnova portfolio) in September 2020. Also partnered with Gyroscope Therapeutics for up to $60M investment (Nov 2021).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-02-14
Description

Acquired Promedior (Sofinnova portfolio, completed Feb 2020) and Spark Therapeutics (Sofinnova portfolio, completed in 2019-2020). Multiple Sofinnova M&A exits.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-15
Description

Acquired Audentes Therapeutics (Sofinnova portfolio) in 2020, completing the acquisition January 15, 2020. Marquee Sofinnova M&A exit in gene therapy.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Large healthcare-dedicated investment firm across private equity, public equity, and royalty/credit strategies. Comparable to Sofinnova in being a healthcare-only, multi-strategy platform investing across therapeutic stages with a doctor/PhD-led team.

TypeDirect peer
Description

Early-stage, healthcare-focused venture firm that partners with entrepreneurs to build therapeutics companies. Comparable to Sofinnova's clinical-stage therapeutics focus and company-creation model, though Atlas skews earlier-stage.

TypeDirect peer
Description

Healthcare-focused venture firm investing across therapeutics, medical devices, and diagnostics with a strong company-creation arm. Comparable to Sofinnova in its therapeutics focus, scientific team, and U.S./Europe footprint.

TypeDirect peer
Description

Early-stage healthcare venture firm focused on building therapeutic platforms from inception. Comparable to Sofinnova in its emphasis on founding-stage biotech and its scientific founder partnership model.

TypeDirect peer
Description

Healthcare-dedicated venture and growth firm investing across therapeutics and medtech. Comparable to Sofinnova in therapeutics focus and in backing clinical-stage companies through to IPO and M&A.

TypeDirect peer
Description

Healthcare-focused crossover fund investing across public and private therapeutics. Comparable to Sofinnova's two-platform (private + public) model and frequent co-investment with Sofinnova in late-stage rounds.

TypeDirect peer
Description

Healthcare and technology venture firm known for early-stage biotech creation and long-duration partnerships. Comparable to Sofinnova as a deep-science VC that co-invests in many of the same portfolio companies.

TypeDirect peer
Description

European healthcare-dedicated venture firm investing in late preclinical and clinical-stage therapeutics. Comparable to Sofinnova in transatlantic therapeutic focus and frequent co-investment (e.g., Coultreon, Capstan).

TypeBroad incumbent
Description

Large, multi-stage venture firm with a sizable healthcare practice alongside technology. Comparable to Sofinnova in healthcare venture investing but operates as a generalist with a broader sector mandate and much larger overall AUM.

TypeDirect peer
Description

Healthcare and technology venture firm with a long history of therapeutics investing. Comparable to Sofinnova in clinical-stage biotech focus and the use of deep scientific expertise to back therapeutic entrepreneurs.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment325 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sofinnova Investments

Venture Capital - Healthcare/Biotech Investmentsofinnova.com

Sofinnova Investments is a US healthcare investment firm managing approximately $4.6B across a private venture capital platform (Funds IV–XII) and the Synergy Fund public-equity hedge fund, backing late preclinical and clinical therapeutic companies in the US and Europe. The firm has funded 118 companies, producing 55 IPOs, 30 M&As, and 33 FDA approvals, including the $14B Karuna→BMS exit.

What Sofinnova Investments does

Sofinnova Investments is a US healthcare investment firm headquartered at 3000 Sand Hill Road in Menlo Park, California, founded in 1972 in Paris and operating in the US since 1976. Following the 1997 separation of the original Sofinnova group into independent US (Sofinnova Ventures) and Paris (Sofinnova Partners) entities, Sofinnova Investments has been the US successor firm. The firm invests in late preclinical and clinical therapeutic companies across the US and Europe in oncology, respiratory, dermatology, ophthalmology, neurology, and women's health, with a cumulative track record of 118 companies funded, 55 IPOs, 30 M&As, and 33 FDA drug approvals. Notable exits include Karuna Therapeutics→Bristol Myers Squibb ($14B), CinCor→AstraZeneca ($1.8B), RayzeBio→BMS, Akouos→Lilly, Audentes→Astellas, Spark→Roche, Principia→Sanofi, and Capstan→AbbVie (June 2025).

The firm operates a two-platform model: a private-markets venture capital platform organized around successive fund vintages (Funds IV through XII, with Fund X at $650M in 2016 the largest disclosed), and a public-markets platform (Synergy Fund) launched in 2017 as an all-cap, value-oriented, long/short global therapeutics hedge fund with emphasis on mid- and small-cap companies. Approximately $4.6B in assets under management and committed capital is managed as of 9/30/2025. Revenue is generated via management fees on committed capital plus performance-based carried interest on exits; LPs access information through a dedicated Investor Portal. Sofinnova's investment team is "mostly comprised of doctors and doctorate holders," and partners hold meaningful board seats in portfolio companies, providing operational support across drug development, FDA/EMA navigation, company building, and IPO/M&A execution. The firm operates regional offices in Boston (Seaport) and New York, with a previously opened La Jolla office whose current operational status is unconfirmed; a tier-1 co-investor ecosystem includes Viking Global Investors, ARCH Venture Partners, Fidelity, Forbion, Novo Holdings, B Capital, RA Capital, Mubadala, and Perceptive Advisors.

Sofinnova Investments firmographics

Firmographics
Name
Sofinnova Investments
Legal name
Sofinnova Investments, Inc.
Website
https://sofinnova.com
Company type
Private
Founded year
1972
Operating status
Operating
Headcount range
51–100 employees
Short description
Sofinnova Investments is a US healthcare investment firm managing approximately $4.6B across a private venture capital platform (Funds IV–XII) and the Synergy Fund public-equity hedge fund, backing late preclinical and clinical therapeutic companies in the US and Europe. The firm has funded 118 companies, producing 55 IPOs, 30 M&As, and 33 FDA approvals, including the $14B Karuna→BMS exit.
Ownership category
akta.pro rank

Sofinnova Investments industry classification

Industry
Product category
Venture Capital - Healthcare/Biotech Investment
NAICS
Portfolio Management and Investment Advice (52394)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAGAG
Endowment / OCIO-Style Multi-Manager Platforms
Financial & Insurance/Private Equity & Venture Capital/Fund-of-Funds / Multi-Manager Platforms

Keywords

  • Venture capital
  • Healthcare investing
  • Biotech investment
  • Therapeutic development
  • Life science funding

Where Sofinnova Investments is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Sofinnova Investments business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Private Equity Investment Returns: Primary revenue stream: capital appreciation and exit proceeds from investments in late preclinical and clinical therapeutic companies across the U.S. and Europe. Realized through IPOs (e.g., Karuna, CinCor, RayzeBio, Aerovate, Bolt, Athira, Vera, Inozyme, NuCana, Principia, Entasis, Iterum, Y-mAbs, Ascendis, Apellis) and M&A acquisitions (e.g., Karuna→BMS $14B, CinCor→AstraZeneca $1.8B, RayzeBio→BMS, Akouos→Lilly, Audentes→Astellas, Spark→Roche, Tesaro→GSK, Principia→Sanofi, Promedior→Roche, Capstan→AbbVie, Gyroscope→Novartis). 55 IPOs and 30 M&As to date.
  2. Public Equity Hedge Fund: All-cap, value-oriented, long/short global therapeutics hedge fund launched in 2017 with emphasis on mid and small-cap companies. Generates management fees and performance-based returns through the Synergy Fund and related public equity strategies.
  3. Fund Management Fees & Carry: Sofinnova raises successive venture funds (Funds IV through XII, with Fund X being the largest at $650M in 2016) and charges typical private equity management fees and performance carry against approximately $4.6B in assets under management and committed capital (as of 9/30/2025).

Pricing tiers

ModelBillingPrice
OtherMulti-year contractVenture Fund X (2016) — largest disclosed fund

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Sofinnova Investments product offering

Product offering

Core offering

Sofinnova Investments is a healthcare-focused investment firm that deploys human and financial capital into late preclinical and clinical therapeutic companies across the U.S. and Europe. It operates a two-platform architecture: a Private Markets venture capital platform that partners with biotech entrepreneurs through every stage of company formation (initial funding, management team building, corporate alliances, IPO and M&A), and a Public Markets hedge fund (Synergy Fund) that pursues an all-cap, value-oriented, long/short global therapeutics strategy.

Product overview

Sofinnova Investments operates a two-platform architecture: a Private Markets venture capital platform and a Public Markets hedge fund (Synergy Fund). The Private Markets platform is the core offering, deploying human and financial capital into late preclinical and clinical therapeutic companies across the U.S. and Europe, with key therapeutic areas including oncology, respiratory, dermatology, ophthalmology, neurology, and women's health. The Public Markets platform, launched in 2017, is an all-cap, value-oriented, long/short global therapeutics hedge fund with an emphasis on mid- and small-cap companies. Limited partners access fund information through the Sofinnova Investor Portal (powered by Altareturn). Sofinnova manages approximately $4.6B in assets under management and committed capital, has funded 118 companies, achieved 55 IPOs, 30 M&As, and 33 FDA drug approvals, with 120 years of operating experience and 100 years of investing experience.

Differentiator

Problem solved

Functional benefit

Products and services

  • Private Markets Platform Venture capital platform partnering with biotech entrepreneurs in the U.S. and Europe, guiding them through all stages of company formation including initial funding, management team building, corporate alliances, M&A, and IPO. Invests in late preclinical and clinical therapeutic companies across oncology, respiratory, dermatology, ophthalmology, neurology, and women's health. Successive funds IV through XII raised since 1998.
  • Public Markets (Synergy Fund) All-cap, value-oriented, long/short global therapeutics hedge fund launched in 2017 with an emphasis on mid- and small-cap companies. The fund is managed by the Public Equity team led by General Partner Eric Delbridge, MD.
  • Sofinnova Investor Portal

Quantifiable outcome

  • 118 companies funded; 55 IPOs; 30 M&As; 33 FDA drugs approved
  • +13 more outcomes

Companies that use Sofinnova Investments

Customer profile

Segments3 records

Ideal customer profiles3 records

Sofinnova Investments technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Sofinnova Investments partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core.

  • Galapagos NVcoreStrategic or Co-development Partner · 28 April 2026Originally developed COL-5671 (a SIK3 inhibitor) and fully transferred it to Coultreon Biopharma in April 2025 with an initial seed investment, then participated in Coultreon's $125M Series A. Strategic asset-transfer and co-investor relationship connected to Sofinnova via Coultreon.
  • Fosun PharmacoreOEM/ Whitelabel/ Licensing Partner · 9 October 2025Granted Expedition Therapeutics (Sofinnova portfolio) exclusive worldwide rights (excluding parts of China) to develop and commercialize EXPD-101, a DPP1 inhibitor for COPD.
  • AbbViecoreStrategic or Co-development Partner · 30 June 2024Acquired Capstan Therapeutics (Sofinnova portfolio) in 2025 to strengthen commitment to transforming patient care in immunology, representing a major strategic exit.
  • BiogencoreStrategic or Co-development Partner · 9 April 2024Entered partnership with City Therapeutics (Sofinnova portfolio) worth up to $1 billion in May 2025, per Fierce Biotech coverage. City Therapeutics planned to supplement its raise through additional partnerships similar to its existing Biogen deal.
  • GSKcoreStrategic or Co-development Partner · 9 January 2024Acquired Aiolos Bio (Sofinnova portfolio) in January 2024. Previously acquired TESARO (Sofinnova portfolio). Strategic acquirer of Sofinnova-backed respiratory and oncology assets.
  • Bristol Myers SquibbcoreStrategic or Co-development Partner · 22 December 2023Acquired Karuna Therapeutics for $14B (Sofinnova Managing Partner Jim Healy served as board member) and RayzeBio (acquired by BMS to add premier radiopharmaceutical platform). Marquee Sofinnova M&A exit partner.
  • AstraZenecacoreStrategic or Co-development Partner · 24 February 2023Acquired CinCor Pharma (Sofinnova portfolio, Jim Healy was Chairman) for $1.8B; the CinCor acquisition was completed in February 2023. AstraZeneca also subsequently acquired ZS Pharma (Sofinnova portfolio).
  • NovartiscoreStrategic or Co-development Partner · 22 December 2022Acquired Gyroscope Therapeutics (Sofinnova portfolio) for up to $1.5B to expand its ophthalmology gene therapy capabilities; Gyroscope acquisition completed February 2022. Novartis also previously acquired Ziarco (Sofinnova portfolio).
  • Eli LillycoreStrategic or Co-development Partner · 1 December 2022Acquired Akouos (Sofinnova portfolio, completed Dec 2022) to expand efforts in genetic hearing loss treatments. Previously partnered with NextCure (Sofinnova portfolio) on immuno-oncology discovery (Nov 2018) and with BioAge (Sofinnova portfolio) on multi-year collaboration for age-related disease targets (Dec 2024).
  • RegeneroncoreStrategic or Co-development Partner · 31 May 2022Completed acquisition of Checkmate Pharmaceuticals (Sofinnova portfolio) in May 2022. Strategic acquirer of Sofinnova-backed immuno-oncology assets.
  • PfizercoreStrategic or Co-development Partner · 28 April 2021Acquired Amplyx Pharmaceuticals (Sofinnova portfolio, completed Apr 2021) and NextWave Pharmaceuticals (Sofinnova portfolio) for pediatric ADHD therapeutics. Acquired Metsera (referenced in 2026 outlook context as a $10B obesity biotech acquisition).
  • MerckcoreStrategic or Co-development Partner · 5 November 2020Acquired VelosBio (Sofinnova portfolio) in November 2020 to add ROR1-directed antibody drug conjugates for oncology.
  • SanoficoreStrategic or Co-development Partner · 28 September 2020Completed acquisition of Principia Biopharma (Sofinnova portfolio) in September 2020. Also partnered with Gyroscope Therapeutics for up to $60M investment (Nov 2021).
  • RochecoreStrategic or Co-development Partner · 14 February 2020Acquired Promedior (Sofinnova portfolio, completed Feb 2020) and Spark Therapeutics (Sofinnova portfolio, completed in 2019-2020). Multiple Sofinnova M&A exits.
  • AstellascoreStrategic or Co-development Partner · 15 January 2020Acquired Audentes Therapeutics (Sofinnova portfolio) in 2020, completing the acquisition January 15, 2020. Marquee Sofinnova M&A exit in gene therapy.

Scale indicators9 records

Recent moves9 records

Expansion highlights5 records

Sofinnova Investments competitors and assessment

Company assessment

Direct peers

  • OrbiMed Advisors: Large healthcare-dedicated investment firm across private equity, public equity, and royalty/credit strategies. Comparable to Sofinnova in being a healthcare-only, multi-strategy platform investing across therapeutic stages with a doctor/PhD-led team.
  • Atlas Venture: Early-stage, healthcare-focused venture firm that partners with entrepreneurs to build therapeutics companies. Comparable to Sofinnova's clinical-stage therapeutics focus and company-creation model, though Atlas skews earlier-stage.
  • Versant Ventures: Healthcare-focused venture firm investing across therapeutics, medical devices, and diagnostics with a strong company-creation arm. Comparable to Sofinnova in its therapeutics focus, scientific team, and U.S./Europe footprint.
  • 5AM Ventures: Early-stage healthcare venture firm focused on building therapeutic platforms from inception. Comparable to Sofinnova in its emphasis on founding-stage biotech and its scientific founder partnership model.
  • Frazier Life Sciences: Healthcare-dedicated venture and growth firm investing across therapeutics and medtech. Comparable to Sofinnova in therapeutics focus and in backing clinical-stage companies through to IPO and M&A.
  • RA Capital Management: Healthcare-focused crossover fund investing across public and private therapeutics. Comparable to Sofinnova's two-platform (private + public) model and frequent co-investment with Sofinnova in late-stage rounds.
  • ARCH Venture Partners: Healthcare and technology venture firm known for early-stage biotech creation and long-duration partnerships. Comparable to Sofinnova as a deep-science VC that co-invests in many of the same portfolio companies.
  • Forbion: European healthcare-dedicated venture firm investing in late preclinical and clinical-stage therapeutics. Comparable to Sofinnova in transatlantic therapeutic focus and frequent co-investment (e.g., Coultreon, Capstan).
  • Venrock: Healthcare and technology venture firm with a long history of therapeutics investing. Comparable to Sofinnova in clinical-stage biotech focus and the use of deep scientific expertise to back therapeutic entrepreneurs.

Broad incumbents

  • New Enterprise Associates (NEA): Large, multi-stage venture firm with a sizable healthcare practice alongside technology. Comparable to Sofinnova in healthcare venture investing but operates as a generalist with a broader sector mandate and much larger overall AUM.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Sofinnova Investments social profiles

Digital presence

Sofinnova Investments compliance and trust

Trust signal

Compliance1 record

Sofinnova Investments financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sofinnova Investments leadership team

Management profile

Number of profiles

Profiles20 records

Sofinnova Investments subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Sofinnova Investments funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sofinnova Investments M&A and investment

M&A and investment

M&A

Investments325 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sofinnova Investments

What does Sofinnova Investments do?

Sofinnova Investments is a healthcare-focused investment firm that deploys human and financial capital into late preclinical and clinical therapeutic companies across the U.S. and Europe. It operates a two-platform architecture: a Private Markets venture capital platform that partners with biotech entrepreneurs through every stage of company formation (initial funding, management team building, corporate alliances, IPO and M&A), and a Public Markets hedge fund (Synergy Fund) that pursues an all-cap, value-oriented, long/short global therapeutics strategy.

Is Sofinnova Investments a public or private company?

Sofinnova Investments is a private company. It is classified as management employee owned and is currently operating.

When was Sofinnova Investments founded?

Sofinnova Investments was founded in 1972. It employs 51 to 100 people.

Where is Sofinnova Investments based?

Sofinnova Investments is headquartered in Menlo Park, United States, in the North America region.

How does Sofinnova Investments make money?

Three revenue lines are on record. Private Equity Investment Returns are the primary driver. The others are public Equity Hedge Fund and fund Management Fees & Carry.

Who are Sofinnova Investments's main competitors?

Direct peers on record are OrbiMed Advisors, Atlas Venture, Versant Ventures, 5AM Ventures, Frazier Life Sciences, RA Capital Management, ARCH Venture Partners, Forbion and Venrock. New Enterprise Associates (NEA) is listed as a broad incumbent.

Does Sofinnova Investments have an API?

No public API is recorded for Sofinnova Investments.

What industry is Sofinnova Investments in?

Sofinnova Investments's product category is Venture Capital - Healthcare/Biotech Investment. Its primary akta.pro industry code is FSANAGAG, Endowment / OCIO-Style Multi-Manager Platforms. Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Sofinnova Investments Adds Former Gilead CMO Merdad Parsey As Executive PartnerSofinnova Investments appointed Merdad Parsey as Executive Partner, adding a biopharmaceutical executive with over 25 years of experience. He previously served as Gilead Sciences' Executive Vice President and Chief Medical Officer, overseeing clinical development and portfolio strategy. Sofinnova manages approximately $4.8 billion in assets as of June 30, 2026.FinancialContent Business PageSofinnova Investments Announces the Appointment of Dr. Merdad Parsey as Executive PartnerSofinnova Investments appointed Dr. Merdad Parsey as Executive Partner, bringing over 25 years of biopharmaceutical experience. He previously served as Executive Vice President and Chief Medical Officer at Gilead Sciences, overseeing clinical development and portfolio strategy. The firm, with $4.8B in assets under management, expects his expertise to support new opportunities and portfolio companies.MorningstarSofinnova Investments Announces the Appointment of Dr. Merdad Parsey as Executive PartnerSofinnova Investments appointed Dr. Merdad Parsey as Executive Partner, bringing over 25 years of biopharmaceutical experience. He previously served as Executive Vice President and Chief Medical Officer at Gilead Sciences. The firm, with $4.8B in assets under management, expects his expertise to support portfolio development.BioWorldExpedition Therapeutics navigates $115M series BExpedition Therapeutics raised $115 million in a series B financing led by General Atlantic. RA Capital, Vivo Capital, and existing investors including Sofinnova, Novo Holdings, and Sanofi Ventures participated. The round was announced on BioWorld Financings Respiratory Series B U.S.WebrazziBiyoteknoloji şirketi Expedition Therapeutics, 115 milyon dolar yatırım aldıExpedition Therapeutics raised $115 million in a B-series round led by General Atlantic. The funds will advance Phase 2 trials of EXPD-101, a DPP1 inhibitor for COPD, and expand its inflammatory disease portfolio. The company aims to develop oral small-molecule therapies for immune-related conditions.FinSMEsExpedition Therapeutics Raises $115M in Series B FundingExpedition Therapeutics raised $115M in Series B financing led by General Atlantic. The funds will advance its lead DPP1 inhibitor EXPD-101 through Phase 2 clinical development and expand its pipeline for inflammatory diseases.MorningstarExpedition Therapeutics Announces Oversubscribed $115 Million Series B Financing to Advance Next-Generation DPP1 Inhibitor for COPDExpedition Therapeutics closed an oversubscribed $115 million Series B financing led by General Atlantic, with participation from RA Capital, Vivo Capital, and existing investors. The funds will advance its lead DPP1 inhibitor EXPD-101 through Phase 2 clinical development, and the first patient has been dosed in the global Phase 2 COPD trial.FinSMEsClaris Biotherapeutics Raises $118M in Series B FundingClaris Biotherapeutics raised $118M in Series B financing led by Samsara Biocapital and Catalio Capital Management. The funds will complete clinical trials for CSB-001 in limbal stem cell deficiency and support a planned 2027 pivotal program. The company also aims to enable pre-commercialization activities.Venture Capital Access OnlineClaris Bio Unveils Development Strategy, Planned Pivotal Study Supported by $118 Million Series B Financing from Top-Tier Investors, and Multiple Leadership AppointmentsClaris Biotherapeutics closed an $118 million Series B financing and appointed Stephen Brady as CEO and Brian Baum as CCO. The funds will support pivotal studies for CSB-001 in limbal stem cell deficiency, planned for 1H 2027, with proof-of-concept results expected in H2 2026.BioSpaceClaris Bio Unveils Development Strategy, Planned Pivotal Study Supported by $118 Million Series B Financing from Top-Tier Investors, and Multiple Leadership AppointmentsClaris Biotherapeutics closed an $118 million Series B financing and appointed Stephen Brady as CEO and Brian Baum as CCO. The funds will support pivotal studies for CSB-001 in limbal stem cell deficiency, planned for 1H 2027, with proof-of-concept results expected in H2 2026.